



Saturday, April 27, 2019
7:00 AM - 3:30 PM

New Paradigms in the Treatment of Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia and Chronic Myeloid Leukemia

Jointly provided by:



Houston Marriott at the
Texas Medical Center

6580 Fannin Street
Houston, TX 77030

Phone: (713) 796-0080

Educational Grants:

Novartis Pharmaceuticals Corporation
Takeda Oncology

To view full slide handouts, visit www.cancernetus.com/leukemia2019

For online registration and more information
visit: www.cancernetus.com



Statement of Need/Program Overview

This symposium is intended to improve care of patients with acute lymphoblastic leukemia (ALL), chronic lymphocytic Leukemia (CLL), acute myeloid leukemia (AML) and chronic myelogenous leukemia (CML) by accelerating adoption of new guidelines and evidence-based practice change. The format will include didactic lectures from known opinion leaders, question and answer sessions, and ample opportunity for participant interaction with faculty.

Target Audience

This symposium is directed primarily to hematologists/oncologists, physician assistants, nurse practitioners, registered nurses, pharmacists and fellows in training interested in new development in ALL, CLL, AML and CML. No specific skill or knowledge other than a basic training in hematology/ oncology is required for successful participation in this activity.

Learning Objectives

After completing this activity, the participant should be better able to:

- Describe the alterations in cytogenetic, molecular abnormalities, NOTCH1, CRLF2 mutations, epigenetic markers in the diagnosis and treatment of patients with acute lymphoblastic leukemia (ALL)
- Identify the novel therapeutic options for adolescents and young adults (AYA) relapsed/refractory Philadelphia-positive and Philadelphia-negative patients with ALL
- Assess the prognostic markers, risk stratification and their impact on clinical practice of patients with chronic lymphocytic lymphoma (CLL)
- Identify and apply individualized treatment strategies based on current and emerging novel therapies for CLL
- Describe the alterations in driver mutations revealing molecular subgroups leading to disease classification and prognostic stratification in acute myeloid leukemia (AML)
- Recognize how compound genotypes are related to clinical outcomes in AML patients treated with novel agents
- Evaluate the first line therapy options for chronic myeloid leukemia (CML) in chronic phase
- Identify response assessment and management of tyrosine kinase inhibitors resistance in the treatment of CML
- Recognize the time-based response milestones and monitoring in patients with CML

Agenda

SATURDAY – October 27, 2018

7:00 AM Onsite Registration and Buffet Breakfast

7:55 AM Opening Remarks *William G. Wierda, MD, PhD*

ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)

8:00 AM Pretest – Case Vignettes *Nitin Jain, MD/Elias Jabbour, MD*

8:15 AM Overview of Diagnosis Based on Cytogenetic and L Molecular Abnormalities in Patients with AL *Nitin Jain, MD*

8:45 AM Novel Therapies for adolescents and young adults (AYA), Philadelphia-positive and Philadelphia-negative Relapsed/ Refractory Patients with ALL *Elias Jabbour, MD*

9:15 AM Posttest – Case Vignettes *Nitin Jain, MD / Elias Jabbour, MD*

9:30 AM BREAK

ACUTE MYELOID LEUKEMIA (AML)

9:45 AM Pretest – Case Vignettes *Courtney DiNardo, MD*

10:00 AM Overview of Disease Classification and Prognostic Stratification in Patients with AML *Courtney DiNardo, MD*

10:30 AM Treatment Options with Novel IDH1/2, FLT3 and CD33 Targeted Agents in Genomic Subgroups of AML *Courtney DiNardo, MD*

11:00 AM Posttest – Case Vignettes *Courtney DiNardo, MD*

CHRONIC MYELOID LEUKEMIA (CML)

11:15 AM Pretest – Case Vignettes *Ghayas C. Issa, MD / Guillermo Garcia-Manero, MD*

11:30 AM Response Assessment and Management of TKIs Resistance in the Management of CML *Ghayas C. Issa, MD*

12:00 PM LUNCH

1:00 PM Understanding of Time-based Response Milestones and Monitoring in Patients with CML *G. Garcia-Manero, MD*

1:30 PM Posttest – Case Vignettes *Ghayas C. Issa, MD / G. Garcia-Manero, MD*

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

1:45 PM Pretest – Case Vignettes *Jan A. Burger, MD, PhD / William G. Wierda, MD, PhD*

2:00 PM Emerging Prognostic Markers and Risk Stratification in Treatment Decision Making for Patients with CLL *Jan A. Burger, MD, PhD*

2:30 PM BREAK

2:45 PM Changing the Treatment Paradigm for CLL: Chemo-immunotherapy versus Targeted Therapy *William G. Wierda, MD, PhD*

3:15 PM Posttest – Case Vignettes *Jan A. Burger, MD, PhD / William G. Wierda, MD, PhD*

3:30 PM Closing Remarks and Adjourn *William G. Wierda, MD, PhD*

Faculty

Jan A. Burger, MD, PhD

Associate Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Courtney DiNardo, MD

Assistant Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Guillermo Garcia-Manero, MD

Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Ghayas C. Issa, MD

Assistant Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Elias Jabbour, MD

Associate Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Nitin Jain, MD

Associate Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

William G. Wierda, MD, PhD

Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Disclosure of Relevant Financial Relationships

A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health and Amedco, assess conflicts of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME/CE activities. All relevant financial relationships are identified and conflicts of interest are resolved prior to the activity to ensure fair balance, scientific objectivity of studies utilized in this activity, and validity of patient care recommendations. Amedco is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Name	Conflict of Interest Disclosures
Jan A. Burger, MD, PhD	Speakers' Bureau: Janssen Research Support: Pharmacyclics, Gilead
Courtney DiNardo, MD	Consultant: AbbVie, Agios, Celgene Advisory Board: Karyopharm Therapeutics, Syros Pharmaceuticals, Jazz Pharmaceuticals, MedImmune
Guillermo Garcia-Manero, MD	Grant and Research Support: Amphivena, Helsinn, Novartis, AbbVie, Celgene, Astex, Onconova, Merck Consultant: Celgene, Astex, Amphivena
Ghayas C. Issa, MD	No relevant financial relationships
Elias Jabbour, MD	Research Support: BMS, AbbVie, Pfizer, Amgen, Takeda, Adaptive Biotechnologies
Nitin Jain, MD	Research Support and Advisory Board: AbbVie, Pharmacyclics, AstraZeneca, Genentech, Verastem, Pfizer, Servier, ADC Therapeutics, Precision Biosciences, Adaptive Biotechnologies Research Support: Collectis, Incyte, Seattle Genetics, Celgene, BMS Advisory Board: Janssen Grant: Andrew Sabin Family Foundation
William G. Wierda, MD, PhD	Advisory Board: Genzyme Research Support: GSK/Novartis, Abbvie, Genentech, Karyopharm, Pharmacyclics LLC, Acerta Pharma, Gilead Sciences, Juno Therapeutics, KITE Pharma, Sunesis, Miragen, Oncternal Therapeutics, Inc., Cyclacel, Loxo Oncology, Inc., Janssen, Xencor
Kamatham A. Naidu, PhD	No relevant financial relationships

All other individuals in a position to control content have no relevant financial relationships to disclose.

Overview of Diagnosis Based on Cytogenetic and Molecular Abnormalities in Patients with ALL

Nitin Jain, MD

**Novel Therapies for adolescents and young adults (AYA), Philadelphia-positive
and**

Philadelphia-negative Relapsed/Refractory Patients with ALL

Elias Jabbour, MD

Overview of Disease Classification and Prognostic Stratification in Patients with AML

Courtney DiNardo, MD

**Treatment Options with Novel IDH1/2, FLT3 and CD33 Targeted Agents in
Genomic Subgroups of AML**

Courtney DiNardo, MD

Response Assessment and Management of TKIs Resistance in the Management of CML

Ghayas C. Issa, MD

Understanding of Time-based Response Milestones and Monitoring in Patients with CML

Guillermo Garcia-Manero, MD

Emerging Prognostic Markers and Risk Stratification in Treatment Decision Making for Patients with CLL

Jan A. Burger, MD, PhD

Changing the Treatment Paradigm for CLL: Chemo-immunotherapy versus Targeted Therapy

William G. Wierda, MD, PhD

New Paradigms in the Treatment of Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia and Chronic Myeloid Leukemia

Physician Continuing Education

Accreditation Statement:



This activity has been planned and implemented in accordance with the accreditation requirements and the policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health and CancerNet, LLC. The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation:

The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health designates this educational activity for a maximum of 6.0 AMA PRA Category 1 Credit(s)[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing and Pharmacist Continuing Education



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and CancerNet LLC. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement: Amedco LLC designates this live activity for a maximum of 6.00 contact hours for nurses and 6.00 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity. Event UAN: JA4008163-9999-19-015-L04-P

Instructions for Claiming AMA PRA Category 1 Credit(s) (Physicians, PAs and NPs):

- In order to receive credit, all attendees must sign-in at the beginning of the activity, submit a completed evaluation and claim credit online through BSWH.md/cmecredit. Instructions on how to complete the evaluation and claiming credit online are included in program handouts.

Participant Requirements for Credit (Nurses and Pharmacists):

- Participants must fully attend all sessions as well as turn in a completed signature verification form (No partial credit will be given). Participants can earn Continuing Education credits for this program by electronically logging onto the website for;
- Nurses and Pharmacists at <http://can.cmecertificateonline.com> and completing the evaluation. After completion of the evaluation, you can print your certificate immediately and one is emailed to you. NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.
- All participant names will be checked against program attendance sheets for verification of attendance.

Disclosure & Evaluation: All participants will have the opportunity to evaluate the educational session and presenter as well as the ability to identify their future educational needs. Disclosure will be made on the day of the program regarding any relevant financial relationship an individual may have with a commercial interest organization.

REGISTRATION New Paradigms in the Treatment of Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia and Chronic Myeloid Leukemia

First Name _____ Middle Initial _____ Last Name _____

Physician Pa-C NP PhD Pharmacist Industry Nurse Other

Mailing Address _____

City _____ State _____ Zip Code _____

Phone _____ Fax _____

E-Mail _____

Speciality _____

Pharmacists only:

NABP e-profile # _____ Birth Date (MMDD): _____

Registration Fee

Registration fee partially covers breakfast buffet, lunch and syllabus book

	Early Registration Fee (Up to 4/15/19)	Discounted Registration Fee (4/16/19 - 4/22/19)	Regular Registration Fee (4/23/19 - 4/27/19)
<input type="checkbox"/> Physicians	\$100.00	\$130.00	\$160.00
<input type="checkbox"/> Registered Nurses, Nurse Practitioners, Physician Assistants	\$75.00	\$95.00	\$115.00
<input type="checkbox"/> Pharmacists, Fellow	\$75.00	\$95.00	\$115.00
<input type="checkbox"/> Industry †	\$350.00	\$400.00	\$450.00

† Person(s) employed by for-profit organizations such as pharmaceutical and biotech companies, and financial institutions

No Refund. Substitution is allowed

Payment may be made: MC Visa Discover Check

Credit Card Number _____ Expiration Date _____

Name and address (as given on the monthly credit card statement) _____

Signature _____

Register online at www.cancernetus.com

Please make checks payable to **CancerNet, LLC**. Mail checks to CancerNet, LLC, 860 Hebron Pkwy, Suite 1104, Lewisville, TX 75057. To reserve your place for the meeting, please complete the registration form and fax it to 443-267-0016. For questions, please call Brian Waggoner at 972-459-5222 or E-mail: brianw@cancernetus.com

Fax registration to:
443-267-0016

Mail registration to:
860 Hebron Pkwy, Suite 1104
Lewisville, TX 75057



For online registration and more information visit: www.cancernetus.com